Exelixis liver cancer drug meets late-stage goal, shares jump

Health Care FOXBusiness

Doctors Jordan Klein (2nd R) and Chane Price (R) confer as University of Miami interns Ignatios Papas (L) and Tim Sterrenberg (2nd L) look on in the Rehabilitation Unit of Jackson Memorial Hospital in Miami, September 30, 2013. The Obama ... administration accelerated its push to persuade individual Americans to sign up for the most extensive overhaul of the U.S. healthcare system in 50 years, the Affordable Care Act (commonly referred to as “Obamacare”) even as the program's foes in Congress fought to delay its launch with the threat of a federal government shutdown. The Jackson Health System is the largest in Florida and one of the largest in the U.S. REUTERS/Joe Skipper (UNITED STATES - Tags: HEALTH) - RTR3FGCZ (Reuters)

Oct 16 (Reuters) - Exelixis Inc. (EXEL) said on Monday its drug to treat patients with a type of liver cancer met the main goal in a late stage study, sending its shares up 19 percent in premarket trading.

Continue Reading Below

The drug, cabozantinib, showed statistically significant improvement in overall survival in advanced hepatocellular carcinoma patients who had been previously treated with Bayer AG and Amgen's sorafenib, compared with a placebo.

Exelixis plans to file for an expanded label for the drug with the U.S. Food and Drug Administration in the first quarter of 2018.

More from FOX Business

The drug, sold under the brand name Cabometyx, is currently used in treating kidney cancer.

Exelixis and France's Ipsen jointly announced a licensing agreement last year for the commercialization and further development of the drug outside the United States, Canada and Japan.

Hepatocellular carcinoma liver cancer is the third-leading cause of death worldwide, making up about three-fourths of the nearly 41,000 cases that will be diagnosed in 2017 in the United States, the company said.

Continue Reading Below

The drugmaker's shares were up 18.74 percent at $29.4 in premarket trading on Monday. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

What do you think?

Click the button below to comment on this article.